Development of the regenerative cell therapy SB618
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「To date, SB618 has shown potential efficacy in nonclinical studies (in vivo studies) targeting peripheral nerve disorders and spinal cord injury. Going forward, development will proceed for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions.」
The policy of proceeding with development of SB618 for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions has been reaffirmed. - FY2020RestatedAnnual report
「Animal studies have confirmed the efficacy of SB618 in peripheral nerve disorders and spinal cord injury. Development is proceeding for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions.」
The policy of developing SB618 as a treatment for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions has been reaffirmed. - FY2019RestatedAnnual report
「Animal studies have confirmed the efficacy of SB618 in peripheral nerve disorders and spinal cord injury. Development is proceeding for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions.」
The development policy for SB618 targeting peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions has been reaffirmed. - FY2017First statedAnnual report
「Animal studies have confirmed the efficacy of SB618 in peripheral nerve disorders and spinal cord injury. Development is proceeding for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions.」
Development of SB618, an enhanced-function mesenchymal stem cell product, is proceeding for peripheral nerve disorders, spinal cord injury, multiple sclerosis and other conditions.